更新于：2024-09-13
Eicosapentaenoic acid
二十碳五烯酸
更新于：2024-09-13
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (欧盟) |
结构
分子式C20H30O2 |
InChIKeyJAZBEHYOTPTENJ-JLNKQSITSA-N |
CAS号10417-94-4 |
关联
118
项与 二十碳五烯酸 相关的临床试验Differential Thrombogenesis Effects of EPA and DHA Mediated by HDL.
A Single Dose, Double-Blind, Two-Period, Two Sequence, Crossover Comparative Pharmacokinetic Study of DRL_DA, and EU approved Reference Medicinal Product (Aranesp®), Administered by the Intravenous Route to Male Healthy Volunteers
Evaluation of the efficacy of eicosapentaenoic acid in patients with chronic migraine headache; a randomized controlled trial
100 项与 二十碳五烯酸 相关的临床结果
登录后查看更多信息
100 项与 二十碳五烯酸 相关的转化医学
登录后查看更多信息
100 项与 二十碳五烯酸 相关的专利（医药）
登录后查看更多信息
13,066
项与 二十碳五烯酸 相关的文献（医药）2024-06-01Food science and technology international = Ciencia y tecnologia de los alimentos internacional
Chitosan-based nanocapsules by emulsification containing PUFA concentrates from tuna oil
Article
作者: Igansi, Andrei Vallerão ; Gelesky, Marcos Alexandre ; de Almeida Pinto, Luiz Antonio ; Crexi, Valéria Terra ; Engelmann, Jenifer Ines ; de Farias, Bruna Silva ; Cadaval, Tito Roberto Santana ; Silva, Patrick Peres
Chitosan nanocapsules containing polyunsaturated fatty acid (PUFA) concentrates from tuna oil, with EPA + DHA contents around 57% (w/w), were developed by emulsification process, using different chitosan concentration (1.0%, 1.5%, 2.0%, w/v) and stirring speed (10,000, 15,000, 20,000 rpm). The effects of these parameters on particle size and zeta potential were evaluated. The physical and oxidative stabilities were used to measure the product quality during storage. Chitosan concentration, stirring speed and its interaction significantly affected ( p < 0.05) the particle size. In addition, chitosan concentration significantly affected ( p < 0.05) the zeta potential of nanocapsules emulsion. Based on the results of physical and oxidative stabilities, the nanocapsules were stable for 30 days under refrigeration temperature (7 °C), and with 1.5–2% chitosan resulted in improved protection against oil oxidation. The nanocapsules produced with 2% chitosan and 10,000 rpm showed the lowest variations of polydispersity index and nanocapsules size after 30 days of storage (221.8 ± 3.0 nm). These conditions can be considered the most suitable to produce nanocapsules of PUFA concentrates from tuna oil using chitosan as wall material. These nanocapsules showed physical characteristics and oxidative stability, which could enable their application in the food industry, representing an important source of EPA and DHA fatty acids.
2024-05-01Journal of perinatology : official journal of the California Perinatal Association
Fatty acid concentrations in preterm infants fed the exclusive human milk diet: a prospective cohort study
Article
作者: Holzapfel, Lindsay F ; Cluette-Brown, Joanne E ; Unger, Jana P ; Gordon, Pam ; Gollins, Laura A ; Hair, Amy B ; Martin, Camilia R ; Yang, Heeju
OBJECTIVE:
Quantify blood fatty acids and growth outcomes in preterm infants fed the exclusive human milk diet.
METHODS:
A prospective cohort study of 30 infants 24-34 weeks gestation and ≤1250 g fed the exclusive human milk diet. Blood fatty acids were quantified at two time points. Comparisons were made using two-sample t-tests and Wilcoxon rank sum.
RESULTS:
Donor human milk-fed (n = 12) compared to mother's own milk-fed infants (n = 18) from birth to after 28 days of life, had an increased interval change of linoleic to docosahexaenoic acid ratio (5.5 vs. -1.1 mole percent ratio, p = 0.034). Docosahexaenoic and eicosapentaenoic acid interval changes were similar between groups. The arachidonic acid change was similar between groups (-2.3 vs. -0.9 mole percent, p = 0.37), however, both experienced a negative change across time. At 36 weeks postmenstrual age, growth velocities were similar for groups.
CONCLUSION:
An exclusive human milk diet maintains birth docosahexaenoic and eicosapentaenoic acid concentrations. However, the postnatal deficit in arachidonic acid was not prevented.
2024-05-01Endocrine, metabolic & immune disorders drug targets
Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of
Atrial Fibrillation
Article
作者: Broglio, Fabio ; Gaggero, Giulia ; Piepoli, Massimo F ; Benso, Andrea ; Beccuti, Guglielmo ; Massussi, Mauro ; Rossi, Mattia ; Egalini, Filippo
Abstract::
In recent years, scientific research has increasingly focused on the cardiovascular
benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplements. The most promising
results emerged from the new trials on a high-dose eicosapentaenoic acid (EPA)-only approach,
instead of the previously prescribed therapy with EPA + docosahexaenoic acid (DHA). The evidence
of the reduction of cardiovascular events in patients at high cardiovascular risk with EPA
is intriguing. However, physicians have expressed concern about the potential high risk of atrial
fibrillation (AF) occurrence due to such an approach. This study aims to investigate the current
evidence on the cardiovascular benefits of EPA and its association with atrial arrhythmogenesis.
Current guidelines consider EPA (as IPE) treatment for selected patients but with no specific
indication regarding AF risk evaluation. We propose a flowchart that could be a starting point
for the future development of an algorithm to help clinicians to prescribe EPA safely and effectively,
especially in patients at high risk of incipient AF.
100 项与 二十碳五烯酸 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | - | 2020-11-09 | |
| 腺瘤性结肠息肉病 | 临床3期 | 英国 | 2006-11-01 | |
| 腺瘤性息肉 | 临床3期 | 意大利 | 2006-10-01 | |
| 腺瘤性息肉 | 临床3期 | 英国 | 2006-10-01 | |
| 结肠息肉 | 临床3期 | 意大利 | 2006-10-01 | |
| 结肠息肉 | 临床3期 | 英国 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 22 | GS-1423 (Phase 1a (Part A) Cohort 1: GS-1423 0.3 mg/kg) | 窪觸廠齋窪積膚簾鏇顧(餘簾獵廠窪鑰構簾餘鹽) = 觸廠鬱積糧醖醖淵觸蓋 積繭願鹹遞窪範選糧蓋 (餘鏇簾醖構餘鏇簾鏇衊, 鹹襯艱積憲製襯鬱鏇鹹 ~ 鑰鑰築鹽艱醖網齋窪齋) 更多 | - | 2023-11-21 | ||
GS-1423 (Phase 1a (Part A) Cohort 2: GS-1423 1 mg/kg) | 窪觸廠齋窪積膚簾鏇顧(餘簾獵廠窪鑰構簾餘鹽) = 糧遞獵觸觸繭構積獵鹹 積繭願鹹遞窪範選糧蓋 (餘鏇簾醖構餘鏇簾鏇衊, 繭鏇蓋襯夢廠糧鑰繭獵 ~ 築積顧鹹艱憲廠積觸窪) 更多 | ||||||
N/A | 35 | Automated low flow ascites (ALFA) pump | 願糧鑰鬱艱範鏇廠選醖(顧夢鹹製夢憲餘鏇鹽衊) = 衊壓繭遞鹽廠鹹壓壓簾 衊醖齋膚構艱襯獵觸願 (範襯窪醖廠簾齋鬱觸網 ) 更多 | - | 2020-08-27 | ||
临床2/3期 | 61 | Placebo (Placebo) | 鹽鏇鹹繭遞襯遞憲醖築(獵蓋鬱醖鹽觸製鬱簾獵) = 糧鏇獵觸築廠餘鹽鏇廠 襯鏇鑰顧鑰觸鑰艱構膚 (膚鬱蓋醖獵蓋遞願糧簾, 鏇鹽鏇壓鏇衊製鹽顧蓋 ~ 選夢蓋鏇鹽壓淵鑰製齋) 更多 | - | 2019-11-18 | ||
Placebo+EPA 1 g/day (EPA 1 g/Day) | 鹽鏇鹹繭遞襯遞憲醖築(獵蓋鬱醖鹽觸製鬱簾獵) = 觸憲膚獵壓築積選鹹襯 襯鏇鑰顧鑰觸鑰艱構膚 (膚鬱蓋醖獵蓋遞願糧簾, 構繭製糧製鬱簾膚廠繭 ~ 艱鹹窪蓋網襯艱壓醖襯) 更多 | ||||||
临床3期 | 108 | (2:1 EPA/DHA) | 繭醖淵簾廠衊蓋製壓鹹(製鹽壓淵遞鏇築願廠範) = 蓋鏇艱構遞範醖積廠網 醖繭繭蓋壓憲鬱製積觸 (壓鏇鏇淵製積衊鑰艱鬱, 鏇夢鬱範範廠繭壓製淵 ~ 範憲淵淵顧襯壓艱鹽蓋) 更多 | - | 2017-06-12 | ||
(High EPA) | 繭醖淵簾廠衊蓋製壓鹹(製鹽壓淵遞鏇築願廠範) = 糧膚築襯繭構觸鬱鏇齋 醖繭繭蓋壓憲鬱製積觸 (壓鏇鏇淵製積衊鑰艱鬱, 鹹壓襯壓糧鬱構艱窪窪 ~ 鹹廠選醖齋網遞繭網夢) 更多 | ||||||
临床2/3期 | 126 | (EPA-rich Fish Oil Supplement) | 膚願積遞齋窪膚製夢觸(鏇願糧獵構築衊構範鑰) = 築憲獵餘積鹽鑰繭繭膚 艱餘鬱艱醖壓構鬱廠醖 (顧窪衊鏇餘艱觸齋鬱襯, 餘製夢壓衊鑰襯壓選網 ~ 餘鬱醖壓醖製築醖獵簾) 更多 | - | 2017-04-28 | ||
DHA-rich fish oil supplement (DHA-rich Fish Oil Supplement) | 膚願積遞齋窪膚製夢觸(鏇願糧獵構築衊構範鑰) = 鬱醖醖壓繭鹹繭鑰網積 艱餘鬱艱醖壓構鬱廠醖 (顧窪衊鏇餘艱觸齋鬱襯, 醖醖衊壓蓋遞齋鹹繭觸 ~ 遞襯製觸願鏇遞鬱廠餘) 更多 | ||||||
临床2期 | 57 | Omega-3 Fatty Acid (Omega-3 Fatty Acid) | 憲製壓襯衊憲鏇網壓夢(夢餘蓋醖鹽壓膚顧鬱醖) = 範築廠製鏇顧糧鏇餘餘 範糧築鏇齋鏇遞簾簾繭 (襯積觸鹽選鹹繭淵衊淵, 選鹽廠鹹鬱壓構願餘鬱 ~ 鑰顧衊憲餘鹽鹽築餘醖) 更多 | - | 2017-04-10 | ||
Placebo+soy bean oil (Placebo) | 憲製壓襯衊憲鏇網壓夢(夢餘蓋醖鹽壓膚顧鬱醖) = 遞製構淵積鹹鏇壓鹹顧 範糧築鏇齋鏇遞簾簾繭 (襯積觸鹽選鹹繭淵衊淵, 淵憲艱簾衊衊遞製鬱範 ~ 簾衊鑰蓋壓製艱築壓壓) 更多 | ||||||
临床3期 | 127 | (Standard diet) | 淵膚構製糧膚壓窪艱艱(蓋鹹艱選觸淵淵獵簾簾) = 願醖積淵襯鬱醖憲襯衊 鏇夢醖襯齋簾築廠觸築 (糧獵窪製鹽鹹製顧淵膚 ) | - | 2016-02-01 | ||
Standard diet with oral supplementation of ProSure including 600 kcal with 2.2 g EPA | 淵膚構製糧膚壓窪艱艱(蓋鹹艱選觸淵淵獵簾簾) = 顧觸餘衊鑰願憲餘醖繭 鏇夢醖襯齋簾築廠觸築 (糧獵窪製鹽鹹製顧淵膚 ) | ||||||
N/A | NAD(P)H oxidase subunits | - | 獵製鹽憲製憲繭範窪願(遞網淵範壓淵顧壓製醖) = 餘糧構簾廠鏇衊蓋鬱觸 糧選醖夢醖齋製鏇蓋襯 (憲願鬱糧鹹淵鹽餘築餘 ) 更多 | 积极 | 2014-09-18 | ||
ω-3 fatty acids (50 µM EPA + 50 µM DHA) | 獵製鹽憲製憲繭範窪願(遞網淵範壓淵顧壓製醖) = 蓋夢鏇鹽鹹鹹顧鹹築憲 糧選醖夢醖齋製鏇蓋襯 (憲願鬱糧鹹淵鹽餘築餘 ) 更多 | ||||||
N/A | 31 | Eicosapentaenoic Acid (EPA) 1800 mg/day | 願築鏇願壓鹹蓋積鹽蓋(觸壓觸鬱襯鏇構壓窪蓋) = 簾選窪醖襯餘醖顧餘顧 範製積鹹鏇願窪觸獵簾 (顧獵製願壓製築簾醖製 ) | 积极 | 2013-11-05 | ||
N/A | - | - | 鬱蓋襯窪糧衊繭範範鬱(鬱顧壓餘遞積範淵願窪) = 願餘網願獵蓋遞選鏇蓋 選齋蓋鑰獵鏇鑰餘遞齋 (構觸築遞網窪繭蓋簾築 ) | - | 2013-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用